title: Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.
abstract: Breast cancers that are negative for estrogen receptor α (ERα), progesterone receptor, and human epidermal growth factor receptor 2 are known as triple-negative breast cancers (TNBC). TNBCs are associated with an overall poor prognosis because they lack expression of therapeutic targets like ERα and are biologically more aggressive. A second estrogen receptor, ERβ, has been found to be expressed in 50% to 90% of ERα-negative breast cancers, and ERβ expression in TNBCs has been shown to correlate with improved disease-free survival and good prognosis. To elucidate the role of ERβ in regulating gene expression and cell proliferation in TNBC cells, the TNBC cell line MDA-MB-468 was engineered with inducible expression of full-length ERβ. In culture, ERβ expression inhibited cell growth by inducing a G1 cell cycle arrest, which was further enhanced by 17β-estradiol treatment. In xenografts, ERβ expression also inhibited tumor formation and growth, and 17β-estradiol treatment resulted in rapid tumor regression. Furthermore, genomic RNA sequencing identified both ligand-dependent and -independent ERβ target genes, some of which were also regulated by ERβ in other TNBC cell lines and correlated with ERβ expression in a cohort of TNBCs from the Cancer Genome Atlas Network. ERβ target genes were enriched in genes that regulate cell death and survival, cell movement, cell development, and growth and proliferation, as well as genes involved in the Wnt/β-catenin and the G1/S cell cycle phase checkpoint pathways. In addition to confirming the anti-proliferative effects of ERβ in TNBC cells, these data provide a comprehensive resource of ERβ target genes and suggest that ERβ may be targeted with ligands that can stimulate its growth inhibitory effects.
authors: McArdle Laboratory for Cancer Research, 1400 University Avenue, University of Wisconsin, Madison, Wisconsin 53705. wxu@oncology.wisc.edu.
authors: Erin K
authors: EK
authors: Shanle
authors: Zibo
authors: Z
authors: Zhao
authors: John
authors: J
authors: Hawse
authors: Kari
authors: K
authors: Wisinski
authors: Sunduz
authors: S
authors: Keles
authors: Ming
authors: M
authors: Yuan
authors: Wei
authors: W
authors: Xu
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004958:Estradiol / Q000502:physiology; D047629:Estrogen Receptor beta / Q000502:physiology*; D005260:Female; D059585:G1 Phase Cell Cycle Checkpoints; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D059467:Transcriptome; D064726:Triple Negative Breast Neoplasms / Q000235:genetics / Q000378:metabolism*
chemical_list: D047629:Estrogen Receptor beta; D004958:Estradiol
references: Breast Cancer Res Treat. 2011 Apr;126(2):395-405
references: 20490651
references: Endocrinology. 2001 Sep;142(9):4120-30
references: 11517191
references: Arthritis Care Res (Hoboken). 2010 Nov;62(11):1588-93
references: 20556817
references: Cancer Res. 2004 Jan 1;64(1):423-8
references: 14729654
references: Endocrinology. 1999 Dec;140(12):5566-78
references: 10579320
references: Endocrine. 2009 Oct;36(2):224-32
references: 19680825
references: Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3799-804
references: 16501043
references: J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):165-75
references: 10418990
references: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
references: 12883005
references: Breast Cancer Res Treat. 2008 Aug;110(3):507-20
references: 17876701
references: Cancer Lett. 2009 Jun 18;278(2):210-219
references: 19217708
references: J Clin Invest. 2011 Jul;121(7):2750-67
references: 21633166
references: Endocrinology. 2003 Oct;144(10):4241-9
references: 14500559
references: Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1566-71
references: 14745018
references: Bioinformatics. 2010 Feb 15;26(4):493-500
references: 20022975
references: Nature. 2005 Jul 28;436(7050):518-24
references: 16049480
references: J Mol Endocrinol. 2005 Apr;34(2):553-66
references: 15821116
references: J Mol Endocrinol. 2004 Aug;33(1):35-50
references: 15291741
references: Physiol Rev. 2007 Jul;87(3):905-31
references: 17615392
references: Nature. 2012 Oct 4;490(7418):61-70
references: 23000897
references: Steroids. 2009 Aug;74(8):635-41
references: 19463683
references: J Mol Endocrinol. 2003 Feb;30(1):13-29
references: 12580758
references: Breast Cancer Res Treat. 2007 Jul;104(1):75-85
references: 17009105
references: J Biol Chem. 2010 Jul 16;285(29):22059-66
references: 20404318
references: Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13162-7
references: 16938840
references: Br J Cancer. 2006 Sep 4;95(5):616-26
references: 16880783
references: Mol Cell. 1999 Apr;3(4):513-9
references: 10230404
references: J Cell Biochem. 2007 Aug 1;101(5):1125-47
references: 17520659
references: Endocrinology. 2004 Jul;145(7):3473-86
references: 15033914
references: Breast Cancer Res Treat. 2008 May;109(2):241-50
references: 17638070
references: Oncogene. 2013 May 9;32(19):2390-402
references: 22751110
references: J Clin Oncol. 2008 Aug 1;26(22):3727-34
references: 18669459
references: BMC Bioinformatics. 2011 Aug 04;12:323
references: 21816040
references: Genome Biol. 2010;11(10):R106
references: 20979621
references: Mod Pathol. 2010 Feb;23(2):197-204
references: 19898422
references: Biochem Pharmacol. 2011 Dec 15;82(12):1940-9
references: 21924251
references: Nat Methods. 2008 Jul;5(7):621-8
references: 18516045
references: Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6991-6
references: 23559372
references: Nature. 2012 Apr 04;486(7403):395-9
references: 22495314
references: Cancer Res. 2006 Dec 1;66(23):11207-13
references: 17145865
references: Genomics. 2008 Mar;91(3):281-8
references: 18178374
references: BMC Genomics. 2011 Jan 14;12:36
references: 21235772